Impurezas de aminoácidos utilizadas para sintetizar proteínas
Detalle del producto
| NO | Productos | Cas no | Indicador de calidad de clave | |||
| Pureza | Max. impureza | Residuos totales de solvente | Humedad | |||
| 1 | Fmoc-β-ala-ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 2 | Fmoc-d-ala-d-ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 3 | FMOC-β-ALA-D-ALA-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 4 | FMOC-ARG (PBF) -Arg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 5 | FMOC-β-ALA-ARG (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 6 | FMOC-D-ARG (PBF) -D-ARG (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 7 | FMOC-β-ALA-D-ARG (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 8 | Fmoc-homoarg (PBF) -homoarg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 9 | FMOC-β-ALA-HOMOARG (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 10 | FMOC-ASN (TRT) -Asn (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 11 | FMOC-β-ALA-ASN (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 12 | Fmoc-asp (otbu) -asp (otbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 13 | FMOC-β-ALA-ASP (OTBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 14 | FMOC-CYS (TRT) -CYS (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 15 | FMOC-β-ALA-CYS (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 16 | FMOC-CYS (ACM) -CYS (ACM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 17 | FMOC-β-ALA-CYS (ACM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 18 | FMOC-GLN (TRT) -GLN (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 19 | FMOC-β-ALA-GLN (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 20 | Fmoc-glu (otbu) -gulu (otbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 21 | FMOC-β-ALA-GLU (OTBU) -OH.H2O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 22 | FMOC-β-ALA-GLY-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 23 | FMOC-His (TRT) -His (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 24 | FMOC-β-ALA-HIS (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 25 | FMOC-ILE-ILE-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 26 | FMOC-β-ALA-ILE-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 27 | Fmoc-leu-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 28 | FMOC-β-ALA-LEU-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 29 | Fmoc-d-leu-d-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 30 | FMOC-β-ALA-D-LEU-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 31 | FMOC-LYS (BOC) -lys (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 32 | FMOC-β-ALA-LYS (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 33 | Fmoc-lys (alloc) -lys (asign) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 34 | Fmoc-β-ala-lys (asign) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 35 | Fmoc-met-met-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 36 | FMOC-β-ALA-MET-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 37 | FMOC-NORM (BOC) -ORN (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 38 | FMOC-β-ALA-NORM (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 39 | Fmoc-phe-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 40 | Fmoc-β-ala-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 41 | Fmoc-d-phe-d-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 42 | Fmoc-β-ala-d-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 43 | Fmoc-pro-pro-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 44 | FMOC-β-ALA-Pro-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 45 | FMOC-SER (TBU) -Ser (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 46 | FMOC-β-ALA-SER (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 47 | FMOC-SER (TRT) -SER (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 48 | FMOC-β-ALA-SER (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 49 | Fmoc-thr (tbu) -thr (tbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 50 | FMOC-β-ALA-THR (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 51 | FMOC-TRP (BOC) -TRP (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 52 | FMOC-β-ALA-TRP (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 53 | FMOC-D-TRP (BOC) -D-TRP (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 54 | FMOC-β-ALA-D-TRP (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 55 | Fmoc-tyr (tbu) -tyr (tbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 56 | FMOC-β-ALA-TYR (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 57 | FMOC-D-TYR (ET) -D-TYR (ET) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 58 | FMOC-β-ALA-D-TYR (ET) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 59 | Fmoc-tyr (me) -tyr (me) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 60 | FMOC-β-ALA-TYR (ME) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 61 | Fmoc-val-val-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 62 | FMOC-β-ALA-VAL-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 63 | Fmoc-d-cit-d-cit-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 64 | FMOC-β-ALA-D-CIT-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 65 | FMOC-β-ALA-DAB-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 66 | FMOC- (3- (2-Naftil) -D-ALA) 2-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 67 | FMOC-β-ALA-3- (2-naftil) -D-ALA-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 68 | FMOC- (3- (3-piridinil) -D-Ala) 2-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 69 | FMOC-β-ALA-3- (3-piridinil) -d-ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 70 | Fmoc- (4-cloro-d-phe) 2-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 71 | Fmoc-β-ala-4-cloro-d-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 72 | FMOC- (D-4APH (TBUCBM)) 2-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 73 | FMOC-β-ALA-D-4APH (TBUCBM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 74 | Fmoc-ap (l-hor) -Aph (l-hor) -Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 75 | FMOC-β-ALA-AFP (L-HOR) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 76 | FMOC-LYS (IPR, BOC) -lys (IPR, BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 77 | FMOC-β-ALA-LYS (IPR, BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 78 | Fmoc-β-ala-aea-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 79 | FMOC-AIB-AIB-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 80 | FMOC-β-ALA-AIB-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 81 | Fmoc-arg-oh | 91000-69-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 82 | H-arg (PBF) -Oh | 200115-86-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 83 | Fmoc-d-arg-oh | 130752-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 84 | HD-ARG (PBF) -OH | 200116-81-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 85 | Fmoc-homoarg-oh.hcl | 208174-14-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 86 | H-homoarg (PBF) -Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 87 | Fmoc-d-homoarg-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 88 | HD-HOMOARG (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 89 | Fmoc-asn-oh | 71989-16-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 90 | H-ASN (TRT) -OH | 132388-58-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 91 | Fmoc-asp-oh | 119062-05-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 92 | H-asp (otbu) -oh | 3057-74-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 93 | Fmoc-cys-oh | 135248-89-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 94 | H-Cys (TRT) -OH | 2799/7/7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 95 | H-cys (ACM) -OH.HCL | 28798-28-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 96 | Fmoc-gln-oh | 71989-20-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 97 | H-Gln (TRT) -OH | 102747-84-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 98 | Fmoc-glu-oh | 121343-82-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 99 | H-Glu (OTBU) -OH.H2O | 2419-56-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 100 | Fmoc-his-oh | 116611-64-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 101 | H-His (TRT) -OH | 35146-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 102 | Boc-his-oh | 17791-52-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 103 | Fmoc-lys-oh | 105047-45-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 104 | H-lys (boc) -oh | 2418-95-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 105 | H-lys (asign) -oh | 6298/3/9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 106 | Fmoc-born-oh.hcl | 201046-57-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 107 | H-Norn (BOC) -OH | 13650-49-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 108 | Fmoc-ser-oh | 73724-45-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 109 | H-SER (TBU) -OH | 18822-58-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 110 | H-SER (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 111 | Fmoc-thr-oh.h2o | 73731-37-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 112 | H-Thr (TBU) -Oh | 4378-13-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 113 | FMOC-TRP-OH | 35737-15-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 114 | H-TRP (BOC) -OH | 146645-63-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 115 | FMOC-D-TRP-OH | 86123-11-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 116 | HD-TRP (BOC) -OH | 201290-11-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 117 | Fmoc-tyr-oh | 92954-90-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 118 | H-tyr (tbu) -oh | 18822-59-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 119 | Fmoc-d-tyr-oh | 112883-29-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 120 | HD-TYR (ET) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 121 | H-tyr (me) -oh.hcl | 67423-44-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 122 | FMOC-D-4APH (CBM) -OH | 324017-22-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 123 | HD-4APH (TBUCBM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 124 | FMOC-LYS (IPR) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 125 | H-Lys (IPR, BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
Acerca de
Compensación
Gentolex proporciona productos de gran calidad, si el cliente aumenta la calidad del producto dentro del marco de tiempo requerido con evidencias suficientes, proporcionaremos el análisis y evaluación necesarios para desencadenar los procedimientos de compensaciones.
Producción
Las capacidades de los productos farmacéuticos alcanzaron toneladas de grado, las capacidades de los productos químicos alcanzan 100tons+ grado, las capacidades están bien equipadas para atender a los clientes en todo el mundo.
Investigación y desarrollo
Cada año, el equipo de I + D establece un plan para desarrollar diferentes productos nuevos, cuando se establecen los objetivos, cada miembro del equipo tendrá que continuar con la responsabilidad de KPI y con la política de incentivos.
